Indaptus Posts $1.8M Q2 Loss and Halts Decoy20 Program
INDP is trading near its 52-week low of $0.92 (9.8% above the low) on light trading volume (0.3× avg).
Summary
Indaptus reported Q2 results with a narrowed loss and disclosed the full discontinuation of its Decoy20 clinical program, leaving no active clinical development. The company has $11.6 million in cash and investments and is pursuing strategic alternatives including a new research collaboration in neurological disorders.
Key Events · Earnings and Guidance · INDP
-
Decoy20 Program Discontinued
The company has discontinued further enrollment in its combination study, has no participants remaining in any ongoing Decoy20 clinical study, and currently has no active clinical development programs.
-
Q2 Net Loss Narrowed to $1.8M
Net loss decreased to $1.8 million for Q2 2026 from $5.2 million in Q2 2025, driven by an 83% reduction in R&D expenses to $0.4 million and a 37% reduction in G&A to $1.4 million.
-
Cash Position of $11.6M
As of June 30, 2026, the company had $7.6 million in cash and cash equivalents plus $4.0 million in short-term investments, improved from the $12 million private placement completed in June 2026.
-
New Research Collaboration
The company began a research collaboration in neurological disorders and sleep as an extension of its immunotherapy research, part of its broader strategic alternatives evaluation.
Analysis · INDP · Life Sciences
Indaptus Therapeutics reported Q2 2026 results showing a significantly reduced net loss of $1.8 million compared to $5.2 million a year ago, driven by an 83% cut in R&D spending. The company disclosed it has discontinued its Decoy20 clinical program entirely, leaving it with no active clinical development programs. Cash and short-term investments total $11.6 million as of June 30, 2026, providing a runway that management says is strengthened but still requires additional financing. The company is pivoting toward strategic alternatives including research collaborations, investments, or acquisitions, with a new collaboration in neurological disorders and sleep already underway. This marks a fundamental shift from a clinical-stage biotech to a strategic holding company evaluating options.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDP was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.5M. The 52-week trading range was $0.92 to $8.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.